Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
DUBLIN, Ireland and BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- Allergan plc, (NYSE:AGN), a leading global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization …